• Return to search results
• Start new search

Investigator(s):
John C. Morris, M.D. Principal Investigator Phone: 301-402-2912 jmorris@mail.nih.gov	Thomas Waldmann, M.D. Protocol Chair Phone: 301-496-6656 tawald@helix.nih.gov
Referral Contact(s):
Suzanne Fioravanti, R.N., B.S.N., O.C.N. Research Nurse Phone: 301-594-6544 Fax: 301-402-1001 fioravas@mail.nih.gov	Guinevere Chun, R.N., B.S.N., O.C.N. Research Nurse Phone: 301-451-7868 Fax: 301-402-1001 gchun@mail.nih.gov

---

Primary Eligibility:

• Histologically or cytologically confirmed T-cell large granular lymphocytic (T-LGL) leukemia
• T-LGL-associated hemocytopenia
• No symptomatic CNS involvement by leukemia
• ≥ 4 weeks since prior interferon, chemotherapy, and/or cyclosporine
• No NY Heart Association class III or IV CHF

---

Treatment Plan:

• Patients will receive monoclonal antibody Mik-beta-1 intravenously over 90 minutes on Day 1 followed by monitoring for side effects, blood levels of the antibody, receptor saturation with the antibody, serum chemistries and blood counts for 6 weeks
• Cohorts of 3-6 patients will receive escalating doses of monoclonal antibody Mik-beta-1 until the maximum tolerated dose (MTD) is determined
• Patients will be followed weekly for 6 weeks and then every 3 months for 9 months

---

Additional Information:

• This trial will be conducted at the NIH Clinical Center in Bethesda, MD. It is open to patients who meet the eligibility requirements, regardless of where they live in the United States.
• There is no charge for medical care received at NIH Clinical Center.
• FAQs about this study - provides information for patients about the trial such as frequency and duration of visits, costs, how to enroll, treatment plan.
• PDQ (Physicians Data Query) - provides additional details about this study for health care providers.

Reviewed: 6/18/08
Updated: 12/11/06